Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (42)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Levy, R.
Right arrow Articles by Lozano, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Levy, R.
Right arrow Articles by Lozano, A. M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Brain, Vol. 124, No. 10, 2105-2118, October 2001
© 2001 Oxford University Press

Lidocaine and muscimol microinjections in subthalamic nucleus reverse parkinsonian symptoms

Ron Levy1, Anthony E. Lang3,4, Jonathan O. Dostrovsky1,3, Peter Pahapill5, John Romas1, Jean Saint-Cyr2,3, William D. Hutchison1,2,3 and Andres M. Lozano2,3

1 Department of Physiology, Faculty of Medicine, University of Toronto, 2 Department of Surgery, University of Toronto, Division of Neurosurgery, 3 The Toronto Western Research Institute, 4 Department of Medicine, University of Toronto, Division of Neurology, The Toronto Western Hospital, Toronto, Canada and 5 Division of Neurosurgery, Medical College of Ohio, Toledo, USA

Correspondence to: Jonathan O. Dostrovsky, Department of Physiology Room 3305, Medical Sciences Building, 1 King's College Circle, University of Toronto, Toronto, Ontario, Canada M5S 1A8 E-mail: j.dostrovsky{at}utoronto.ca

Inactivation of neurones in the subthalamic nucleus (STN) of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treated monkey model of Parkinson's disease has been shown to relieve parkinsonian motor symptoms. In patients with Parkinson's disease, neurones in the STN display hyperactive firing rates and rhythmic discharge activity such as tremor-related oscillations (3–8 Hz) and synchronous high-frequency oscillations (15–30 Hz). In this study, microinjections of lidocaine (n = 4) and muscimol, a GABAA receptor agonist (n = 2), were performed in the STN of six patients with Parkinson's disease to determine whether the focal suppression of STN neuronal activity can lead to an improvement in tremor, bradykinesia and rigidity. We also report the first use of microelectrode recording of the effects of microinjections on neuronal activity in the human brain (n = 2). Microinjections of 10–23 µl of lidocaine produced striking improvements in bradykinesia, limb tremor and rigidity in three out of three patients. These improvements were correlated with good therapeutic effects of subsequent STN deep brain stimulation performed in the same microelectrode trajectories as these injections. The most dramatic observation following lidocaine injections was the appearance of dyskinetic limb movements. In one patient, simultaneous microelectrode recording during an injection of 3.5 µl of lidocaine demonstrated a suppression of neuronal activity at distances of <0.9 mm from the injection site, but no suppression was observed at >=1.2 mm from the injection site. Microinjections of 5–10 µl of muscimol in a region with tremor-related activity resulted in suppression of limb tremor in two out of two patients. Interestingly, in one of these patients, 4 Hz oscillatory activity was diminished in a neurone recorded 1.3 mm from the injection site, but there was no reduction in the mean firing rate or 20 Hz oscillatory activity. These results demonstrate that inactivation of neuronal activity in the STN of patients with Parkinson's disease improves motor symptoms. These findings also suggest that a focal block of the STN might alter the oscillatory activity of neurones located beyond the inhibited region.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
ScienceHome page
V. Gradinaru, M. Mogri, K. R. Thompson, J. M. Henderson, and K. Deisseroth
Optical Deconstruction of Parkinsonian Neural Circuitry
Science, April 17, 2009; 324(5925): 354 - 359.
[Abstract] [Full Text] [PDF]


Home page
J. Neurophysiol.Home page
M. Weinberger, W. D. Hutchison, A. M. Lozano, M. Hodaie, and J. O. Dostrovsky
Increased Gamma Oscillatory Activity in the Subthalamic Nucleus During Tremor in Parkinson's Disease Patients
J Neurophysiol, February 1, 2009; 101(2): 789 - 802.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
K. Mukhida, M. Hong, G.B. Miles, T. Phillips, B.A. Baghbaderani, M. McLeod, N. Kobayashi, A. Sen, L.A. Behie, R.M. Brownstone, et al.
A multitarget basal ganglia dopaminergic and GABAergic transplantation strategy enhances behavioural recovery in parkinsonian rats
Brain, August 1, 2008; 131(8): 2106 - 2126.
[Abstract] [Full Text] [PDF]


Home page
J. Neurophysiol.Home page
S. Ramanathan, T. Tkatch, J. F. Atherton, C. J. Wilson, and M. D. Bevan
D2-Like Dopamine Receptors Modulate SKCa Channel Function in Subthalamic Nucleus Neurons Through Inhibition of Cav2.2 Channels
J Neurophysiol, February 1, 2008; 99(2): 442 - 459.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
M.-L. Welter, J.-L. Houeto, A.-M. Bonnet, P.-B. Bejjani, V. Mesnage, D. Dormont, S. Navarro, P. Cornu, Y. Agid, and B. Pidoux
Effects of High-Frequency Stimulation on Subthalamic Neuronal Activity in Parkinsonian Patients
Arch Neurol, January 1, 2004; 61(1): 89 - 96.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
N. Maurice, A.-M. Thierry, J. Glowinski, and J.-M. Deniau
Spontaneous and Evoked Activity of Substantia Nigra Pars Reticulata Neurons during High-Frequency Stimulation of the Subthalamic Nucleus
J. Neurosci., October 29, 2003; 23(30): 9929 - 9936.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
C.-H. TAI, T. BORAUD, E. BEZARD, B. BIOULAC, C. GROSS, and A. BENAZZOUZ
Electrophysiological and metabolic evidence that high-frequency stimulation of the subthalamic nucleus bridles neuronal activity in the subthalamic nucleus and the substantia nigra reticulata
FASEB J, October 1, 2003; 17(13): 1820 - 1830.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
W Hamel, U Fietzek, A Morsnowski, B Schrader, J Herzog, D Weinert, G Pfister, D Muller, J Volkmann, G Deuschl, et al.
Deep brain stimulation of the subthalamic nucleus in Parkinson's disease: evaluation of active electrode contacts
J. Neurol. Neurosurg. Psychiatry, August 1, 2003; 74(8): 1036 - 1046.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
S. B. Evans, C. W. Wilkinson, P. Gronbeck, J. L. Bennett, G. J. Taborsky Jr., and D. P. Figlewicz
Inactivation of the PVN during hypoglycemia partially simulates hypoglycemia-associated autonomic failure
Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2003; 284(1): R57 - R65.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
J. Luo, M. G. Kaplitt, H. L. Fitzsimons, D. S. Zuzga, Y. Liu, M. L. Oshinsky, and M. J. During
Subthalamic GAD Gene Therapy in a Parkinson's Disease Rat Model
Science, October 11, 2002; 298(5592): 425 - 429.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.